Jump to content

Reynsie48

Members
  • Posts

    48
  • Joined

  • Last visited

Profile Information

  • Interests
    Knitting, Crochet, Computer Games

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. Jean, I can so empathize with you. Often before I start the wash, I will bury my face in one of Ron's shirts and think what if...... I think I would be very much like you, and I am glad that you posted Sandy
  2. Merck KGaA Resumes Stimuvax Clinical Program in Lung Cancer * FDA lifts clinical hold on START clinical trial Darmstadt, Germany, June 17 2010 –Merck KGaA and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine*) clinical program in patients with non-small cell lung cancer (NSCLC), which includes the Phase III studies, START(a) and INSPIRE(. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees. “Merck remains highly committed to the development of BLP25 liposome vaccine and the well-being of the patients. We believe this therapeutic cancer vaccine has the potential to be a valuable addition to the future range of therapies for oncologists and their patients,” said Dr. Wolfgang Wein, Executive Vice President, Oncology of the Merck Serono division. This announcement follows a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for BLP25 liposome vaccine in March 2010 and allow the START trial to be resumed. “Merck worked constructively with the FDA and other health authorities to address the questions raised on the safety of BLP25 liposome vaccine in patients with NSCLC and, as a result, we can now resume our NSCLC clinical program,” commented Dr. Bernhard Kirschbaum, Head of Global Research and Development of the Merck Serono division. “We have meanwhile received a number of regulatory approvals to restart in other countries and await approval in the remaining countries.” The study that remains on clinical hold by the FDA is the Phase III STRIDE© trial in advanced breast cancer. Merck will continue to work closely with health authorities, including the FDA, to decide the next steps for this trial. "The resumption of the BLP25 liposome vaccine clinical program is very good news for the oncology community and NSCLC patients. If the START and INSPIRE Phase III trials are successful, BLP25 liposome vaccine could play an important role in the treatment of these currently underserved patients," said Dr. Frances Shepherd, Director of the Medical Oncology Princess Margaret Hospital in Toronto, Ontario, Canada, and Coordinating Investigator of the START trial. Merck temporarily suspended its global clinical program for BLP25 liposome vaccine in all recruiting studies worldwide following the clinical hold put in place by the FDA in March 2010. The clinical hold followed a suspected unexpected serious adverse reaction (SUSAR) of encephalitis, observed in a patient enrolled in an exploratory Phase II trial of BLP25 liposome vaccine in patients with multiple myeloma. To ensure the safety of the study subjects, the protocols in the NSCLC trials are being amended to add specific safety measures. a) START: Stimulating Targeted Antigenic Responses To NSCLC INSPIRE: Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response c) STRIDE: STimulating immune Response In aDvanced brEast cancer * BLP25 liposome vaccine is an experimental therapy that has not been approved for commercial distribution. About Stimuvax Merck is investigating the use of Stimuvax® (BLP25 liposome vaccine) in the treatment of NSCLC. The vaccine was granted fast-track status for NSCLC in September 2004 by the FDA. Merck KGaA obtained the exclusive worldwide licensing rights from Oncothyreon Inc., Seattle, Washington, USA. Stimuvax is being developed in Europe by Merck. In the United States and Canada, Stimuvax is being developed by EMD Serono, an affiliate of Merck KGaA. The START study is a Phase III, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety and tolerability of Stimuvax in subjects suffering from unresectable, stage IIIA or IIIB non-small cell lung cancer (NSCLC) who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study will involve more than 1,300 patients in approximately 30 countries. The primary endpoint of the START study is overall survival (OS). The INSPIRE study is a Phase III, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety and tolerability of Stimuvax in subjects suffering from unresectable, stage IIIA or IIIB non-small cell lung cancer (NSCLC) who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The design of the INSPIRE study is almost identical to the START study. INSPIRE will enrol approximately 420 unresectable, stage III NSCLC patients across China, Hong Kong, Korea, Singapore and Taiwan. Study participation is expected to last for a minimum of 24 months. STRIDE is a randomized, double-blind, controlled, multi-center Phase III study designed to determine if Stimuvax can extend progression free survival in patients treated with hormonal therapy who have inoperable, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study.
  3. Prayers for Katie and Rick! Sandy
  4. A Happy and Blessed Easter Sunday to you too Judy and to each and everyone on the board from Guleph Ontario. It is beautiful here, hot in the sun, cool in the shade and I walked around the hospital grounds after eating my lunch out in the sun sitting on a bench. Unfortunately I have to work my yearly month of days in April but it is so nice to look forward to the beautiful weather that will be waiting when I finish at 3pm and the Hubby that will be waiting for me to enjoy a nice Easter supper out with. This is one of those times that I am reminded that there are still many special times to be thankful for! Sandy
  5. Reynsie48

    Bill Has Died

    Barbara, Tears are good! I can only hope to follow your and Bill's example if and when the time arises. For now, I wish you peace. Sandy
  6. Reynsie48

    Bill Has Died

    Barbara, I am so very sorry to hear this. I have followed your's and Bill's story for so long I feel like I have lost him too! Rest in Peace Bill. Sandy
  7. Barb, I wish you continued strength during your journey with Bill! Sandy
  8. Bonnie, I am so very sorry for your loss. Sandy
  9. From what I understand from Ron's trial nurse is that yes, the Start trial has yet to reach it's quota of patients and that it has been somewhat difficult. Many who might qualify decide not to take a chance on the randomization of 2/1, and others leave the trial because of progress in their disease. Ron asked his Oncologist a few visits back, how long he might stay on this trial and of course the answer is indefinitely, or till progression or you choose to leave it. I guess until the maximum number of patients has been enrolled, they don't reach randomization so he feels we may be looking at years down the road. We are aware that Ron was treated very aggressively because of his good performance rating when he was first discovered to have cancer, stage 3 (Squamous), unresectable not only because of mediastinal involvement but because the original mass was around his pulmonary artery and the risk of "nicking" the artery during surgery and bleeding to death was too great. His radiation oncologist (who was the first one to give us the grim news of 6 to 8 months without treatment, 12 to 18 months with) was also the same Doctor who all along said that Ron was one of a few patients that he felt might just "squeak" through the door, and this was from one of the first appointments, and months pre trial. As Dr. West has pointed out, stage 3a NSCLC is treated with curable intent and therefore Ron may have done well either way. For myself, I enjoy the continued extra surveillance that comes with participation in the trial, and although the hope is to maintain the status of no evidence of recurrent disease that he achieved around December of 2008. Today Ron became 64 years old and we head out for the Doctors’ in a couple of hours, and then to the Cancer Centre on Wednesday, but we really don’t mind sharing birthdays with the “Docs”, just so very glad that the birthdays are there to share. Sandy
  10. (((((Bonnie))))) Prayers for you, for Howard and for your children to help you all ! Sandy
  11. Lynnie, Such a beautiful tribute to your Father. My deepest sympathies to you and your family. Sandy
  12. Hello Barbara, So sorry to hear that Bill is having problems again. I am no where near an expert but if it were my husband, I would push to get an antibiotic for the infection along with a regimen for treating and dressing the bed sore. A bedsore left untreated with or without an infection will get worse and sepsis is a real worry but as well, they can become extremely painful. I am not sure whether or not this would be considered aggressive treatment but in my book would not only make sense but also be competent medical care. It has been some time since I have nursed but even back when we worked on geriatrics you treated a bed sore and or an infection with whatever was necessary. Just my thoughts, Sandy
  13. Melanie, such great news to hear! Congratulations Sandy
  14. Reynsie48

    my new birthday

    Wow! Happy Birthday Geri Sandy
  15. Dear Anne, I am so sorry that you are going through this and I wish I had not only some wisdom for you but some answers as well. It pulls at my heart strings as I could very easily end up in a similar situation and it has often crossed my mind. I too work outside the home and we put a huge dent in our savings for me to take 3 months off and go with Ron when he first went through treatment. This is not something that would be easy to do again and to amplify the problem by Ron actually thinking I didn't want him home would be a breaking point for me. Up here where I am, at our centre, they are trying to treat the cancer patient and the cancer patient's family as a whole as they recognize that it is a disease that deeply affects the whole family and I would hope that dealing with life's necessities such as working to pay the bills, keep up health insurance, stay sane, etc., etc., would be recognized as a priority but obviously there is a lot of work to be done there. This is a problem that will continue to get worse as younger and younger people end up with lung cancer and other cancers. I accept the fact that if the situation were reversed and I was the one with the cancer, that a fact of life would be Ron continuing to daily work and that I will have to manage a fair amount on my own but at this time can't even imagine how we would cope. As it is, we consider Ron a luckier one as he is back to work, it has not been easy as he tires and will soon be 64 but he is the one with the benefits and because he had good benefits they were able to "rehabilitate" him and exert a lot of pressure on him to return to the work force full time as insurance companies have yet to recognize or be able to measure the long lasting after effects of treatment. I hope that you are able to persevere in finding a solution that leaves you feeling safe about your husband while you continue to be the bread winner. You don't need any extra stress! Best wishes and good luck. Sandy
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.